Should You Get a Bone Scan Before Starting a Weight-Loss Injection?

What does a weight-loss injection actually do to your bones?

Weight-loss injections don't appear to attack bone directly — instead, bone is lost as a side effect of losing weight quickly. GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) drive substantial, rapid weight loss, and the skeleton responds to that loss the same way it responds to any large drop in body weight.

A 2025 review in Bone Research sets out four mechanisms behind weight-loss-induced bone loss: reduced mechanical loading (a lighter body puts less force through the skeleton), changes in bone marrow fat that can hold back the cells that build bone, hormonal shifts, and nutritional gaps Liu H, et al. Weight loss induced bone loss. Bone Research, 2025.. On the hormonal side, that same review describes reduced levels of IGF-1, oestrogen and parathyroid hormone during weight loss — a combination that nudges the skeleton towards breaking bone down faster than it rebuilds it.

This framing matters, because it means the bone loss seen with these injections is largely a weight-loss problem, not a poisoning problem — and weight-loss-related bone change is something you can monitor and work to limit.

Who is most at risk of bone loss on Ozempic, Wegovy or Mounjaro?

Not everyone faces the same risk. The people who need to think hardest about their bones are those whose skeletons are already vulnerable — and those losing weight fastest. The Bone Research review specifically names post-menopausal women as a group whose risk is exacerbated, because the drop in oestrogen at menopause already accelerates bone loss Liu H, et al. Bone Research, 2025..

The clinical-trial data point the same way. In a 2024 phase 2 trial published in EClinicalMedicine, once-weekly semaglutide lowered bone mineral density at the total hip (estimated treatment difference −0.020 g/cm² versus placebo; p=0.001) and the lumbar spine (−0.018 g/cm²; p=0.007) over 52 weeks, in a group that was mostly post-menopausal women Hansen MS, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk. EClinicalMedicine, 2024.. Notably, the semaglutide group lost about 6.8 kg more weight than placebo — and the authors link that larger weight loss to the bigger fall in bone density. In other words, the more (and faster) you lose, the more bone tends to go with it.

A separate 2025 review in Osteoporosis International adds a note of caution for older and higher-risk groups: in the large SELECT trial, hip and pelvic fracture rates were higher in women on semaglutide than placebo (1.0% vs 0.2%), and higher again in people aged 75 and over (2.4% vs 0.6%) Karam L, et al. Effects of GLP-1 receptor agonists on bone health in people living with obesity. Osteoporosis International, 2025.. These are observations from one trial population, not proof that the drug causes fractures — but they reinforce that age and existing fragility deserve extra attention.

In short, the higher-risk groups are:

• Post-menopausal women and men aged 50 or over.
• Older adults, especially those aged 75+.
• Anyone with a low body weight to begin with, or a known clinical risk factor for fragility fracture.
• People undergoing rapid, large weight loss.

So should you get a bone scan before starting a weight-loss injection?

Here's the honest answer: no UK guideline currently tells you to get a bone scan specifically before a weight-loss injection. So this is a prevention-first decision — Screen My Bones' position — rather than established NHS, NICE or MHRA guidance. We think that's worth saying plainly, because a lot of online content implies a scan is "required" when no such requirement exists.

What the evidence does support is risk-stratified osteoporosis assessment in the people most likely to have thin bones. The 2024 UK clinical guideline from the National Osteoporosis Guideline Group (NOGG) recommends a FRAX fracture-risk assessment in any post-menopausal woman, or man aged 50 or over, who has a clinical risk factor for fragility fracture; those at intermediate risk are referred for a bone density (DXA) measurement, and those at high risk get a baseline scan to compare future measurements against Gregson CL, et al. The 2024 UK clinical guideline for the prevention and treatment of osteoporosis (NOGG). Archives of Osteoporosis, 2025.. That guidance also flags low body weight as a significant risk factor for hip fracture.

The catch is that NOGG was not written with weight-loss injections in mind, and no published guideline yet defines how — or whether — to screen people before starting one. Indeed, a 2025 review in Osteoporosis International treats the right way to assess bone in this group as an open research question, calling for studies to work out the best clinical use of DXA, vertebral fracture assessment, FRAX and bone turnover markers in people on these drugs — rather than recommending them as a settled baseline protocol Karam L, et al. Osteoporosis International, 2025..

If you want to talk it through, you can book a screening or read about our bone health assessment first.

What does a bone scan before a weight-loss injection actually measure?

A bone density scan measures bone mineral density (BMD) — the amount of mineral packed into your bone — at key sites such as the hip and spine, and gives you a baseline number. That number is only half the value. The other half comes later: when you repeat the scan, the comparison tells you whether your bone density is holding steady or drifting down as the weight comes off.

This is exactly the gap a baseline fills. Without one, any future scan stands alone — you can see where your bones are, but not which way they're heading. With a baseline taken before or early in treatment, a follow-up scan answers the question that actually matters: is my bone density changing, and do I need to act?

It's worth keeping perspective on size. In a small 20-week pilot study of older adults on a GLP-1 medication, researchers found no statistically significant change in whole-body bone density (p=0.77), regional bone density, or bone turnover markers at around 5% weight loss — and noted that the bone loss expected from that amount of weight loss sits within the margin of error of the measurement, calling for larger, longer trials Dinkla L, Beavers KM, et al. BMD and turnover response to GLP-1 receptor agonists. Frontiers in Aging, 2025.. Early data like this suggests that over short periods and modest weight loss, changes may be small — which is precisely why a clear baseline and repeat measurements matter for spotting a real trend over a longer course of treatment.

Why a radiation-free REMS scan may be worth considering for repeat monitoring

If the goal is to monitor bone density over time, the method you choose matters — because the value is in repeating it. A standard DXA scan uses a small dose of X-ray radiation, which makes frequent re-scanning less appealing. REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely across a one- or two-year course of treatment.

The accuracy is reassuring. A 2025 systematic review of 17 studies covering 11,664 patients reported REMS diagnostic concordance with DXA of 63.6–90%, with sensitivity of 70–91.7% and specificity of 73.2–95.5%, and described it as well suited to people who need frequent imaging or who should avoid radiation Icatoiu E, et al. REMS — A Novel Tool in the Diagnosis of Osteoporosis. Diagnostics (Basel), 2025.. You can read more about how the technology works and the science behind our approach.

What can you do alongside your injection to protect your bones?

Whether or not you have a scan, the day-to-day habits that protect bone are the same — and the research is consistent about what works. The single most reliable lever is movement that loads the skeleton.

International advisory guidance for people on GLP-1 therapy — a 2025 joint advisory from several US nutrition and obesity societies — recommends strength (resistance) training at least three times a week plus at least 150 minutes a week of moderate aerobic activity, a higher protein intake during active weight loss (around 1.2–1.6 g/kg/day is proposed), and proactive attention to at-risk nutrients such as vitamin D, calcium and B12 Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity. Obesity (Silver Spring), 2025.. This is US-led guidance rather than UK guidance, but it lines up with the broad picture.

For UK context on the bone-protective basics, NOGG guidance supports weight-bearing and muscle-strengthening exercise, adequate calcium, and vitamin D where insufficiency is identified as part of osteoporosis prevention NOGG, Archives of Osteoporosis, 2025..

In practice, that means:

• Resistance training 2–3 times a week to load muscle and bone.
• Weight-bearing activity — walking, stairs, dancing.
• Adequate protein to help defend lean muscle, which in turn supports bone.
• Calcium and vitamin D sufficiency — discuss supplements with your GP or pharmacist if your diet falls short.
• A baseline scan so you have something to measure progress against.

For the fuller picture on why bone and muscle move together on these drugs, see our companion guide on Ozempic and bone loss.

When should you go back for a follow-up bone assessment?

The honest answer is that there's no official re-scan schedule for weight-loss-injection users, because no guideline yet covers this group — so any interval is a practical judgement, not a rule. What we can say is that bone changes are gradual, and a single scan only becomes powerful when there's a second one to compare it to.

A sensible, prevention-first approach is to take a baseline before or early in treatment, then revisit once you've had a meaningful period of weight loss — often around the 12-month mark, or sooner if you're losing weight unusually fast or already had low bone density at baseline. Because REMS is radiation-free, repeating it carries no radiation cost, which gives you flexibility to re-check when it makes sense for you. Practice parameters note REMS suitability for frequent and annual monitoring. Bone & Joint Open, 2025.

The aim isn't to scan endlessly — it's to turn a silent, invisible risk into something you can see and respond to. If your bone density is holding steady, that's reassurance. If it's drifting, you've caught it at the stage where exercise, nutrition and a conversation with your clinician can do the most good.

You can book a radiation-free bone health assessment, explore our assessment days, or see where we screen across the UK.

---

This article is part of our weight-loss medications and bone health series. For the deeper dive on whether the drugs themselves cause bone loss, read Do Ozempic and weight-loss injections cause bone loss?. If you're navigating menopause too, our menopause and bone health guides cover the added oestrogen factor.